GlassScriptPhysician profile
Jess H Mullens
NPI 1699031369
$33,386.16
in general payments reported to CMS, 2019-2025
26 companies · $5,987 in 2025
The $5,987 reported for 2025 was more than what 84% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,714 · 2020: $785 · 2021: $7,176 · 2022: $9,987 · 2023: $2,295 · 2024: $2,441 · 2025: $5,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,746 · Travel and Lodging: $4,666 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Entertainment: $61.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,746.19 |
| Travel and Lodging | $4,665.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Entertainment | $61.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $10,258.52 | 2019-2024 | Distal Extremities Implants Trauma Ankle Fracture, Distal Extremities Implants Trauma |
| Restor3d, INC. | $5,495.58 | 2025 | |
| Stryker Corporation | $5,231.39 | 2019-2025 | Inbone, Charlotte, Augment Injectable |
| Prime Surgical, LLC | $3,764.77 | 2021-2025 | |
| Crossroads Extremity Systems, LLC | $2,630.00 | 2020-2021 | |
| Bioventus LLC | $1,510.71 | 2019-2025 | Durolane, Exogen Ultrasound Bone Healing System, Supartz Fx Sodium Hyaluronate |
| Organogenesis INC. | $1,257.42 | 2021-2025 | Puraply, Cygnus Dual |
| Depuy Synthes Sales INC. | $684.54 | 2019-2024 | Na, Hammerlock, Motoband |
| Zimmer Biomet Holdings, INC. | $498.42 | 2020-2022 | |
| Alon Medical Technology | $348.60 | 2019 | |
| Smith+Nephew, INC. | $261.56 | 2021 | |
| Sanara Medtech INC. | $235.41 | 2023 | Celleraterx |
| Curonix LLC | $186.99 | 2022-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biocomposites INC | $184.10 | 2023-2024 | Stimulan |
| Paragon 28, INC. | $151.46 | 2020-2023 | Grappler |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $126.02 | 2019-2021 | |
| In2bones USA, LLC | $121.63 | 2020 | |
| Heraeus Medical, LLC. | $111.34 | 2024 | |
| Wright Medical Technology, INC. | $84.58 | 2019 | |
| Kerecis Limited | $72.83 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Medshape, INC. | $51.21 | 2019 | |
| Treace Medical Concepts, INC. | $47.73 | 2024 | |
| Vericel Corporation | $22.79 | 2023 | Maci |
| Polynovo North America LLC | $22.23 | 2025 | Novosorb Btm |
| Kci USA, INC. | $18.95 | 2021 | |
| Orthofix Medical, INC. | $7.38 | 2025 | Physio-Stim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jess Mullens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.